Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.66 EUR | +2.10% | +14.05% | +75.83% |
04-17 | Medincell: share price rises following agreement with AbbVie | CF |
04-16 | Medincell, AbbVie to Co-Develop Injectable Therapeutics | DJ |
Business Summary
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Number of employees: 138
Sales per Business
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Products Received under Development Benefit
58.6
%
| 4 | 97.5 % | 6 | 58.6 % | +45.37% |
Licenses, Milestones
29.3
%
| - | - | 3 | 29.3 % | - |
Royalties
12.0
%
| 0 | 2.5 % | 1 | 12.0 % | +1,077.23% |
Sales per region
EUR in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 4 | 100.0 % | 10 | 100.0 % | +141.78% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 08/01/03 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 31/08/23 |
Chief Tech/Sci/R&D Officer | - | 31/12/14 | |
Sébastien Magnat
COO | Chief Operating Officer | - | 31/08/16 |
Chief Tech/Sci/R&D Officer | - | 31/12/07 | |
Richard Malamut
CTO | Chief Tech/Sci/R&D Officer | 64 | 08/05/22 |
Grace Kim
IRC | Investor Relations Contact | - | 18/09/23 |
- | - | ||
Julie Alimi
LAW | General Counsel | - | - |
Franck Pouzache
HRO | Human Resources Officer | - | 31/03/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 04/07/17 |
Tone Kvåle
BRD | Director/Board Member | 55 | 12/06/22 |
Virginie Lleu
BRD | Director/Board Member | - | 24/05/16 |
Philippe Guy
CHM | Chairman | - | 15/11/10 |
Elisabeth Kogan
BRD | Director/Board Member | - | 14/12/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 28,750,645 | 14,369,906 ( 49.98 %) | 30,646 ( 0.1066 %) | 49.98 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
MEDINCELL S.A. 0.03% | 7,550 | 0.03% | 78,197 $ |
Company contact information
Sector
Sales per Business
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+75.83% | 389M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- MEDCL Stock
- Company MedinCell S.A.